1KaajaE, KaajaR, HiilesmaaV. Major malformations in offspring of women with epilepsy[J]. Neurology, 2003,60(4) :575 -579.
2Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy [ J ]. J Neurol Neurosurg Psychiatry, 2004,75 ( 11 ):1575 - 1583.
3Pennell PB. The importance of monotherapy in pregnancy [ J ]. Neurology,2003,60(11Suppl 4) :S31 -38.
4Yerby MS. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation[J]. Epilepsia, 2003,44 ( Suppl 3 ):33-40.
5Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation[J]. Neurology,2003,61 (6 Suppl2) :S35 -42.
6Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs and lifestyle on malformations and drug exposure (MADRE) [J]. Epilepsia, 2000,41:1436 - 1443.
7Matalon S, Schechtman S, Gddzmig G,et al. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures[ J]. Reprod Toxical, 2002,16:9-17.
8Holmes L, Wyszynski D, Mittendorf R.Evidence for an increased risk of birth defects in the offspring of women exposed to valproate: findings from the AED pregnancy registry [ J ]. Am J Obstet Gynecol, 2002,187:5137.
9Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study[ J ]. Acta Paediatr, 2004,93 ( 2 ):174 - 176.
10Duncan S, Mercho S, Lopes - Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality[ J]. Epilepsia, 2001,42:750-753.
9Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations[J]. Neurology. 2006, 67(3): 407- 412.
10Hemandez - Diaz S, Werler MM, Walker AM, et al. Folicacid antagonists during pregnancy and the risk of birth defect[J]. N Engl J Med, 2000, 343(22):1 608- 1 614.
